Spotlight
 |
Announcing the U.S. launch of Abbott Vascular's flagship drug eluting
stent, the XIENCE V Everolimus Eluting
Coronary Stent System. |
|
|
|
 |
10,000+ Reasons to Believe Abbott Vascular exceeds 10,000 patient enrollments across its Carotid Artery Stenting (CAS) trials. |
|
|
|
 |
Reimbursement Resource Keep up with the latest information on coverage, coding and payment for coronary, carotid and other peripheral procedures related to Abbott Vascular devices. |
|
|
|
Investors & Media
- Abbott's XIENCE V™ Drug Eluting Stent Outperforms TAXUS® in Key Efficacy and Safety Endpoints Out to Two Year
- FDA Approves Abbott's XIENCE™ V Drug Eluting Stent
- Abbott Submits Application for Approval of XIENCE™ V Everolimus Eluting Coronary Stent System in Japan
- Abbott Launches Next-Generation StarClose® SE Vascular Closure System
- XIENCE™ V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
- XIENCE™ V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
AP2928724 Rev A
